A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Lanifibranor (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Acronyms NATIVE
- Sponsors Inventiva Pharma
- 02 Jan 2018 Planned End Date changed from 1 Oct 2018 to 1 Feb 2019.
- 02 Jan 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2019.
- 10 Jun 2017 Biomarkers information updated